Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2008

ion from 2:00 p.m. to 6:00 p.m. local time on

Sunday, June 1, 2008.

-- "Dose effect of ipilimumab in patients with advanced melanoma: results

from a phase 2, randomized, dose-ranging study" (Abstract #9025,

Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.

to 6:00 p.m. local time on Sunday, June 1, 2008.

-- "Prolonged survival in objective responders to ipilimumab therapy"

(Abstract #20004) -- Publication only.

Response and Safety Data of Ipilimumab in Prostate

-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with

radiotherapy (XRT) in patients with metastatic castration resistant

prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for

Patients with Prostate Cancer Session) -- Oral presentation beginning

at 11:30 a.m. local time on Monday, June 2, 2008.

-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate

cancer and ipilimumab in patients with metastatic hormone-refractory

prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)

-- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on

Saturday, May 31, 2008.

Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs

-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal

antibody, in patients with selected refractory or relapse malignancies"

(Abstract #3006, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:00 p.m. local time on

Saturday, May 31, 2008.

-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in

combination with ixabepilone in preclinical tumor models" (Abstract

#3048, Developmental Therapeutics: Immunotherapy Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. loca
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. Medarex to Receive Milestone Payment from Amgen
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)...   Oligomerix, Inc. , a privately held company pioneering ... (AD) and related neurodegenerative disorders, announced today the relocation ... as of January 15, 2014 and expanded ... Medical College. Oligomerix, which is focused on ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... , WAYNE, Pa., Nov. 20 Escalon Medical Corp. ... quarter ended September 30, 2009. , For the ... or 2.7%, to $8,435,000 during the three-month period ended September ... year. The Company reported the decreased net revenue of ...
... 20 Unilens Vision Inc. (OTC Bulletin Board: UVICF; ... and markets specialty contact lenses, today reported its operating ... (FY2010). , Net sales excluding royalty income, were $1,683,673 ... reported in the previous year first quarter (FY2009). ...
Cached Medicine Technology:Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... FDA-approved device has been shown to reduce seizures in ... percent. When coupled with an innovative electrode placement planning ... the complete elimination of seizures in nearly half of ... trials. , That,s good news for a large portion ... with epilepsy whose seizures can,t be controlled with medications ...
(Date:4/22/2014)... of all lung cancers are small cell lung ... resistance to chemotherapy. However, researchers at Virginia Commonwealth ... into the mechanisms leading to this resistance that ... work primarily by mediating B-cell lymphoma 2 (Bcl-2) ... death. Depending on their function, this family of ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... care spending, a new RAND study concludes that U.S. ... companies and device makers to develop products that produce ... and their use, a new study suggests the study ... get created in the first place. The aim is ... loss of health as possible and to ensure that ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... to highlight month long fund raising events to find ... Ted,Strickland has officially declared November as Tay-Sachs Awareness Month,and ... genetic,testing and the need for research to help find ... found most frequently in Ashkenazi Jews, French,Canadians, Louisiana Cajuns, ...
... breakdown, in the epidermis , , FRIDAY, Nov. 2 (Health ... the biological mechanism by which stress increases susceptibility to ... the basis of the stress," said study author Dr. ... of California, San Francisco, and the VA Medical Center, ...
... Institute,s ,Hope Coach, Mobile Mammography Van Features ... Siemens, MAMMOMAT NovationDR Digital System, MALVERN, ... installation of a mobile digital mammography,system in the U.S. ... as part of the Nevada Cancer Institute,s,(NVCI) new Hope ...
... capacity to perceive, comprehend and regulate one,s own emotions and ... between emotions and use this information as a guide for ... developing this type of intelligence is the ability to learn ... changing social and cultural world more effectively. , The Stress ...
... Nov. 2 MedQuist Inc. (Pink,Sheets: MEDQ) announces that ... of strategic alternatives for the Company, is,evaluating whether a ... of the,Company and its shareholders, in light of the ... its decision to proceed,with the sale of its 70% ...
... Limited (ASX: PGL; Nasdaq: PGLA) today announced that ... to PI-88 for the,prevention of tumour recurrence following ... to commence the Phase 3 program as rapidly ... the Special Protocol,Assessment process. The Company has ...
Cached Medicine News:Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 2Health News:Governor Strickland Declares November Tay-Sachs Awareness Month 3Health News:Stress Robs Skin of Antimicrobial Defenses 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
... Control is a liquid control ... busy immunoassay laboratory. With a ... serum based control can replace ... products for immunoassay and therapeutic ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
The Acceava Trichomonas Rapid Test is an immunochromatographic assay that detects pathogen antigens directly from vaginal swabs. Results are rapid, occurring within approximately 10 minutes....
Medicine Products: